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Summary
The AMP-activated protein kinase (AMPK) is a critical regulator of energy balance at both the cellular and whole-body
levels. Two upstream kinases have been reported to activate AMPK in cell-free assays, i.e., the tumor suppressor LKB1
and calmodulin-dependent protein kinase kinase. However, evidence that this is physiologically relevant currently only
exists for LKB1. We now report that there is a significant basal activity and phosphorylation of AMPK in LKB1-deficient
cells that can be stimulated by Ca2+ ionophores, and studies using the CaMKK inhibitor STO-609 and isoform-specific
siRNAs show that CaMKKβ is required for this effect. CaMKKβ also activates AMPK much more rapidly than CaMKKα in
cell-free assays. K+-induced depolarization in rat cerebrocortical slices, which increases intracellular Ca2+ without disturb-
ing cellular adenine nucleotide levels, activates AMPK, and this is blocked by STO-609. Our results suggest a potential
Ca2+-dependent neuroprotective pathway involving phosphorylation and activation of AMPK by CaMKKβ.Introduction
The AMP-activated protein kinase (AMPK) system acts as a
sensor of cellular energy status. Any cellular stress that causes
a fall in the cellular ATP:ADP ratio (either by inhibiting ATP syn-
thesis or by increasing ATP consumption) causes a large rise
in AMP due to the near-equilibrium reaction catalyzed by ade-
nylate kinase (2ADP4 ATP + AMP) (Hardie and Hawley, 2001).
This activates AMPK, which then switches on alternative cata-
bolic pathways that generate ATP, while switching off ATP-
requiring processes that are not essential to short-term sur-
vival, either by direct phosphorylation of target enzymes or by
longer-term effects on gene and protein expression (Carling,
2004; Hardie, 2004; Kahn et al., 2005). As well as regulating
energy balance at the cellular level, it has recently become
clear that AMPK regulates energy balance in mammals at the
whole-body level by mediating effects of adipokines and gut
hormones such as leptin, adiponectin, and ghrelin (Kahn et al.,
2005). AMPK exists as heterotrimeric complexes comprising a
catalytic α subunit and regulatory β and γ subunits, each of
which occurs as two or more isoforms encoded by distinct
genes (Hardie et al., 2003). The α subunits (α1 and α2) contain
conventional kinase domains at the N terminus and are only
active after phosphorylation at a critical residue within the acti-
vation loop, Thr-172 (Hawley et al., 1996), by upstream ki-
nase(s). The β subunits (β1 and β2) contain two conserved do-
mains, a central glycogen binding domain that targets AMPK
to glycogen particles and a C-terminal domain required for as-
sembly of the αβγ complex (Hudson et al., 2003; Polekhina et
al., 2003). The γ subunits (γ1, γ2, and γ3) contain four tandem
sequence repeats termed CBS motifs (Bateman, 1997). TheseCELL METABOLISM : JULY 2005 · VOL. 2 · COPYRIGHT © 2005 ELSEVIform two “Bateman domains” (Kemp, 2004) that bind the regu-
latory nucleotides AMP and ATP with positive cooperativity
(Scott et al., 2004). Binding of AMP activates the kinase by
promoting phosphorylation at Thr-172 by the upstream kinase
and by inhibiting dephosphorylation by protein phosphatases,
as well as by direct allosteric activation (Hardie et al., 1999).
These effects are antagonized by high concentrations of ATP,
which competes with AMP for binding to both Bateman do-
mains (Scott et al., 2004).
For many years, the identity of the upstream kinases that
activate AMPK by phosphorylation at Thr-172 on the α subunit
was unclear. In 1995, we reported that calmodulin-dependent
protein kinase kinase (CaMKK) could phosphorylate and acti-
vate the AMPK complex in cell-free assays (Hawley et al.,
1995). However, the major upstream kinase (AMPKK) purified
from rat liver (Hawley et al., 1996) was not calmodulin depen-
dent and therefore did not appear to be CaMKK. Attempts to
identify the upstream kinase in rat liver extracts by conven-
tional protein purification were not successful. However, two
groups recently reported the identification of three protein ki-
nases encoded in the yeast (Saccharomyces cerevisiae) ge-
nome, i.e., Elm1, Pak1, and Tos3, that phosphorylated the
yeast ortholog of the α subunit of AMPK (Snf1) at the equiva-
lent site (Thr-210) and provided genetic evidence that these
acted upstream of Snf1 in a redundant manner in vivo (Hong
et al., 2003; Sutherland et al., 2003). The nearest relatives of
Elm1, Pak1, and Tos3 in the human genome are the β isoform
of CaMKK and the tumor suppressor kinase LKB1. Three
groups (Hawley et al., 2003; Shaw et al., 2004; Woods et al.,
2003) subsequently provided strong evidence that LKB1, in a
complex with two accessory subunits, STRAD and MO25, is aER INC. DOI 10.1016/j.cmet.2005.05.009 9
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of HeLa cells expressing active or inactive versions of LKB1,
and mouse embryo fibroblasts (MEFs) from LKB1-deficient
embryos, showed that LKB1 was both necessary and sufficient
for phosphorylation and activation of AMPK in response to the
drugs 5-aminoimidazole-4-carboxamide (AICA) riboside and
phenformin (Hawley et al., 2003; Shaw et al., 2004).
Although AMPK was not activated by AICA riboside or phen-
formin in MEFs or HeLa cells lacking LKB1, a low basal activity
of AMPK, and phosphorylation of Thr-172 on the α subunits,
remained. This suggested that there might be an upstream ki-
nase acting on Thr-172 in these cells other than LKB1. The
obvious candidate was a CaMKK, in view of the close similari-
ties of the kinase domains of the CaMKKs with those of Elm1,
Pak1, Tos3, and LKB1 and because pig brain CaMKK (possibly
a mixture of the α and β isoforms) had previously been shown
to phosphorylate and activate AMPK in cell-free assays (Haw-
ley et al., 1995). In this paper, we demonstrate that the
CaMKKs, especially CaMKKβ, represent alternative upstream
kinases for AMPK, in addition to LKB1.
Results
The basal AMPK activity in LKB1−/− MEFs is sensitive
to protein phosphatase treatment
We previously showed that, while the AMPK activities in
LKB1−/− MEFs and HeLa cells that do not express LKB1 were
low, they were nevertheless detectable, and a faint signal was
also obtained using a phosphospecific antibody against Thr-
172 (Hawley et al., 2003). This suggested that there might be
an upstream kinase other than LKB1 phosphorylating Thr-172
in these cells, but it was important to rule out two other pos-
sible explanations: (1) that AMPK might have some basal activ-
ity even in a completely unphosphorylated state and (2) that
the antibody was not completely phosphospecific. To address
these issues, we immunoprecipitated AMPK from the LKB1+/+
and LKB1−/− MEFs and measured the activity after treatment
with the catalytic subunit of protein phosphatase-2A (PP2A) in
the presence and absence of the PP2A inhibitor okadaic acid.
Figure 1 shows that, in the absence of okadaic acid, PP2A
caused a 90% decrease in AMPK activity from the LKB1+/+
cells and that this was associated with a dephosphorylation of
Thr-172, as expected. However, PP2A also caused a large
(>85%) decrease in the AMPK activity from LKB1−/− cells
(which was already lower than that obtained from the LKB1+/+
cells), and this was associated with an almost complete loss
of the signal using the anti-pT172 antibody. These results show
that there is a significant phosphorylation of AMPK at Thr-172
even in cells completely lacking LKB1.
AMPK is activated in response to the calcium
ionophore A23187
Since the CaMKKs are Ca2+/calmodulin activated, if they act
upstream of AMPK in intact cells, one would expect an in-
crease in cytosolic Ca2+ to cause phosphorylation and activa-
tion of AMPK. Figure 2A shows that this was indeed the case:
in HeLa cells, the Ca2+ ionophore A23187 activated AMPK ap-
proximately 10-fold with a maximal effect at 10 M and a half-
maximal effect at 1–2 M. The Ca2+ ionophore ionomycin had
similar effects (data not shown). Since it was possible that in-
cubation with a Ca2+ ionophore might activate AMPK through10Figure 1. Effect of protein phosphatase treatment on AMPK immunoprecipitated
from LKB1+/+ and LKB1−/− mouse embryo fibroblasts
AMPK was immunoprecipitated from extracts with a mixture of anti-α1 and
-α2 antibodies and the precipitates treated with the catalytic subunit of protein
phosphatase-2A (PP2A) in the presence or absence of the phosphatase inhibitor
okadaic acid. The upper panel shows the results (mean ± SEM, n = 3) of subse-
quent AMPK assays in the immunoprecipitates. The lower panel shows Western
blots of the same samples probed with anti-pT172 antibodies or a mixture of
anti-α1 and -α2 antibodies (AMPK-α).a secondary mechanism involving depletion of cellular ATP, we
also measured the cellular ATP:ADP ratio using capillary elec-
trophoresis of perchloric acid extracts. This showed that, while
high concentrations of A23187 (30 M) did cause some de-
crease in the ATP:ADP ratio, there was no effect at 10 M, by
which point the activation of AMPK was already maximal (Fig-
ure 2A). By probing blots with a phosphospecific antibody, the
effect of A23187 on AMPK activity was shown to be associated
with increased phosphorylation of Thr-172, with no change in
the expression of the total AMPK α subunits (Figure 2B).
A23187-induced AMPK activation is antagonized
by the CaMKK inhibitor ST0-609
HeLa cells do not express LKB1 (Hawley et al., 2003), which
cannot therefore be responsible for the phosphorylation of Thr-
172 under these circumstances. Consistent with the idea that
it was catalyzed instead by an isoform of CaMKK, the activa-
tion by A23187 was sensitive to STO-609, an inhibitor of
CaMKK-α and -β (Tokumitsu et al., 2002). Half-maximal inhibi-
tion occurred at about 1 M STO-609 at all concentrations of
A23187 (Figure 2C), suggesting that CaMKKs might be respon-
sible for both the basal and the A23187-stimulated activation
of AMPK.
As reported previously (Hawley et al., 2003), the basal AMPK
activity was higher in HeLa cells that stably express active
LKB1 compared with HeLa cells that express kinase-inactive
LKB1, and the activity was further stimulated by phenformin
only in cells expressing active LKB1. Neither the basal nor the
phenformin-stimulated activities in these cells were reduced
significantly by concentrations of STO-609 up to 25 M (Figure
3A). AMPK activity was increased by A23187 by a similarCELL METABOLISM : JULY 2005
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609 on AMPK activity and ATP:ADP ratios in HeLa cells lacking LKB1
HeLa cells were incubated with various concentrations of A23187 for 60 min.
Where STO-609 was added, cells were preincubated with the inhibitor for 60 min
before addition of A23187. Extracts were prepared and immunoprecipitated with
a mixture of anti-α1 and -α2 antibodies and the immunoprecipitates assayed for
AMPK ([A] and [C]; means ± SEM, n = 2) or analyzed using Western blotting with
anti-pT172 antibodies or a mixture of anti-α1 and -α2 antibodies (AMPK-α).CELL METABOLISM : JULY 2005Figure 3. Effect of the kinase inhibitor STO-609 on AMPK activity and acetyl-CoA
carboxylase phosphorylation in HeLa cells expressing wild-type or inactive LKB1
Cells expressing wild-type (wt) LKB1 or inactive, kinase-dead (KD) LKB1 were
preincubated with various concentrations (A and B) or 25 M (C) of STO-609 for
60 min and then incubated with 5 mM phenformin (A) or 2.5 M A23187 (B and
C), following which AMPK activities (A and B) or phosphorylation of ACC (C) was
analyzed. All results are expressed as mean ± SEM, n = 2.amount in cells expressing active LKB1 as in cells expressing
inactive LKB1, although the basal activity was much lower in
the latter case. In cells expressing active LKB1, the A23187-
stimulated activity was abolished by STO-609, but a substan-
tial basal activity that was resistant to the inhibitor remained.
STO-609 completely abolished both the basal and the A23187-
stimulated activity in cells expressing inactive LKB1 (Figure
3B). These experiments were also carried out with the parental
HeLa cells that do not express any LKB1, and the results were
essentially identical to those obtained with the cells expressing
inactive LKB1 (data not shown).
We also analyzed the phosphorylation of a downstream tar-
get of AMPK, acetyl-CoA carboxylase (ACC), as a marker of
AMPK activity in the intact cells. We used a dual labeling strat-
egy using as probes a phosphospecific antibody against the
AMPK phosphorylation site, and streptavidin to determine total
ACC content. The probes were labeled with different fluores-
cent dyes, which allowed us to quantitatively determine theamounts of phosphorylated ACC and total ACC in a single blot.
The results (Figure 3C), which are expressed as the signal ob-
tained with the phosphospecific antibody relative to that ob-
tained with streptavidin, were consistent with the results of
measurement of AMPK activity in the cell extracts. The basal
level of ACC phosphorylation in HeLa cells expressing wild-
type LKB1 (wt LKB1) was much higher than in cells expressing
an inactive mutant of LKB1 (KD LKB1). In both cell types, the
phosphorylation increased in response to A23187 treatment,
although the effect was much larger in the cells expressing in-
active LKB1, where the basal phosphorylation of ACC was
much lower. The increased phosphorylation in response to
A23187 was completely abolished by the presence of the
CaMKK inhibitor STO-609 in the cells expressing inactive LKB1,
while it was also reduced in cells expressing active LKB1. Re-11
A R T I C L Esults obtained with parental HeLa cells lacking any LKB1 ex-
pression were very similar to those obtained using the cells
expressing inactive LKB1 (data not shown). It should be noted
that the effect of STO-609 on ACC phosphorylation could be
due to inhibition of both CaMKK and AMPK by STO-609 (see
below).
STO-609 is a selective but not a specific
inhibitor of CaMKKs
STO-609 was reported to be a specific inhibitor of CaMKKα
and CaMKKβ, based on tests with seven other protein kinases
(Tokumitsu et al., 2002). To more extensively assess the speci-
ficity of this compound, we tested it against a panel of 23 pro-
tein kinases, including AMPK and LKB1 (Figure 4A). At a con-
centration expected to cause almost total inhibition of bothFigure 4. Selectivity of the kinase inhibitor STO-609 for a range of different pro-
tein kinases
(A) Inhibition of a panel of 23 protein kinases by 10 M STO-609; (B) inhibition
of CaMKKα, CaMKKβ, AMPK, and LKB1 by increasing concentrations of STO-
609. Abbreviations for the kinases and methods of purification and assay were
described previously (Bain et al., 2003). In (B), data were fitted using GraphPad
Prism to the following equation: activity = 100 − (100 × [STO-609]/[IC50 + (STO-
609)]). Estimates of IC50 are quoted in the text, and the curves are the theoretical
curves derived using those values for IC50. In both (A) and (B), individual data
points are means ± SEM, n = 2.12CaMKK isoforms (10 M), three kinases in the panel, i.e.,
AMPK, CK2, and DYRK, were inhibited by more than 50%; a
second group of eight by 20%–50%; and a third group of 12,
including LKB1, by 20% or less. Figure 4B shows the effect of
different concentrations of STO-609 on the activity of CaMKKα,
CaMKKβ, AMPK, and LKB1, with the CaMKK isoforms being
isolated by selective immunoprecipitation of a preparation of
CaMKK from rat brain that contains both isoforms (see below).
The concentrations giving 50% inhibition (IC50) of CaMKKα
and CaMKKβ were 410 ± 20 nM and 230 ± 30 nM, respectively.
Tokumitsu et al. (2002) also found that CaMKKβ was slightly
more sensitive to inhibition than CaMKKα, with comparable
IC50 values, although, because the inhibitor is competitive with
ATP, the exact values depend on the ATP concentration used
in the assay. STO-609 also inhibited AMPK with an IC50 of 1.7 ±
0.1 M, which is 4- and 7-fold higher than the IC50 values for
CaMKKα and CaMKKβ, respectively. The finding that STO-609
inhibits AMPK affects the interpretation of experiments involv-
ing studies of ACC phosphorylation in intact cells (Figure 3C).
However, it does not interfere with assays of AMPK in immuno-
precipitates after incubation of cells with the inhibitor, because
the inhibition of AMPK was completely reversed if the kinase
was assayed in the washed and resuspended immunoprecipi-
tate (data not shown). High concentrations of STO-609 also
inhibited the recombinant LKB1:STRADα:MO25α complex
(Figure 4B), but significant inhibition did not occur at concen-
trations below 10 M, and the estimated IC50 was 33 ± 4 M,
which is two orders of magnitude higher than the values for
CaMKKα and CaMKKβ. Inhibition of LKB1 by STO-609 is not
a significant factor in intact cells, because incubation of HeLa
cells with concentrations of STO-609 up to 25 M had no ef-
fect on the activation of AMPK by phenformin, an effect that is
completely dependent on LKB1 (Figure 3).
Activation of AMPK by A23187 is reduced
by siRNAs targeted at CaMKKβ
Although STO-609 can therefore be used to distinguish be-
tween effects mediated by CaMKKs and LKB1, we sought to
confirm the involvement of CaMKKs in the effects of A23187
using a small interfering RNA (siRNA) approach. Figure 5A
shows that three siRNAs targeted against CaMKKβ caused a
variable but highly significant degree of reduction in AMPK
activities in HeLa cells, while three siRNAs targeted against
CaMKKα had no significant effect. The CaMKKβ siRNAs re-
duced both the basal and the A23187-stimulated AMPK activi-
ties, consistent with the results obtained with STO-609 and
suggesting that the basal phosphorylation is also mediated by
CaMKKβ. The control shown in Figure 5A was an siRNA tar-
geted against glyceraldehyde phosphate dehydrogenase
(GAPDH), which had no effect on AMPK activity when com-
pared with untreated cells or cells treated with an siRNA of
random sequence (Ambion negative control 1, not shown). Fig-
ure 5B (upper panel) shows that we obtained a faint signal for
CaMKKα by Western blotting in the HeLa cells, which was
abolished by all three siRNAs targeted against CaMKKα but
not CaMKKβ. Figure 5B (lower panel) shows that CaMKKβ was
readily detected by Western blotting in the HeLa cell extracts
and that a variable reduction in the expression of that isoform
was obtained using the siRNAs targeted against CaMKKβ but
not CaMKKα. The CaMKKα and CaMKKβ polypeptides de-
tected by these antibodies in HeLa cells migrated with the ex-CELL METABOLISM : JULY 2005
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HeLa cells were pretreated for 48 hr with three siRNAs targeted against CaMKKα
(α1, α2, α3), CaMKKβ (β1, β2, β3), or a control siRNA (GAPDH) (each siRNA at
50 nM). Cells were then incubated with A23187 (2 M) or vehicle. AMPK activity
([A], mean ± SEM, n = 2), and expression of CaMKKα and CaMKKβ using anti-
peptide antibodies (Anderson et al., 1998) (B) were then measured. (C) is a quan-
tification of anti-CaMKKβ blots identical to those shown in (B) (mean ± SEM,
n = 2).pected apparent molecular mass (56 and 65 kDa, respectively)
and comigrated with the major polypeptides detected using
the same antibodies in mouse brain extracts (data not shown).
Quantification of the anti-CaMKKβ blot (Figure 5C) showed that
the siRNA that had the largest effect on the basal and A23187-
stimulated AMPK activity (β3) also had the largest effect on
CaMKKβ expression, whereas the other two CaMKKβ siRNAs
had smaller effects on both parameters. The β3 siRNA consis-
tently reduced both basal and A23187-stimulated AMPK activ-
ity in HeLa cells in three experiments performed at separate
times. It also reduced the phosphorylation of ACC but had no
effect on expression of ACC or the AMPK α subunit (data not
shown).
CaMKKα and CaMKKβ activate AMPK
in a Ca2+/calmodulin-dependent manner
It has previously been reported that CaMKKβ expressed in
E. coli has a higher basal activity and is less dependent onCELL METABOLISM : JULY 2005Ca2+ and calmodulin than CaMKKα (Anderson et al., 1998;
Tokumitsu et al., 2001), although, when it was expressed in
human cells, it was more Ca2+/calmodulin dependent (Tokum-
itsu et al., 2001). Since the siRNA experiments (Figure 5) sug-
gested that it was the β isoform of CaMKK that was acting
upstream of AMPK in the LKB1-deficient HeLa cells, we exam-
ined whether CaMKKβ activates AMPK in a Ca2+/calmodulin-
dependent manner in cell-free assays.
We initially expressed human CaMKKβ as a glutathione
S-transferase (GST) fusion in E. coli. Activation of a GST fusion
of the bacterially expressed kinase domain of AMPK-α1 (GST-
α1) (Scott et al., 2002) using low concentrations of this prepa-
ration of CaMKKβ was stimulated 3- to 4-fold by Ca2+ plus
calmodulin (Figure 6A). We also prepared CaMKKα and CaMKKβ
from a purified preparation of native CaMKK from rat brain
(Edelman et al., 1996) by immunodepletion of the other isoform
using isoform-specific antibodies. Figure 6B shows that the
isoform preparations were not crosscontaminated as judged
by Western blotting. Figure 6C shows that the preparations of
CaMKKα and CaMKKβ from rat brain, measured by their ability
to activate GST-α1, were both stimulated 2- to 3-fold by Ca2+
and calmodulin. When the concentrations of the two isoforms
were equalized for their ability to activate calmodulin-depen-
dent protein kinase I (CaMKI), CaMKKβ activated AMPK 7-fold
more rapidly than CaMKKα. We also compared the effects of
100 M AMP on the activation of the native AMPK complex
purified from rat liver (which is a mixture of the α1 and α2
isoforms of the catalytic subunit associated with β1 and γ1)
by LKB1, CaMKKα, and CaMKKβ. Although the activation of
the AMPK heterotrimer by LKB1 was stimulated 2.4-fold by
AMP, similar to results reported previously (Hawley et al., 2003),
AMP did not have a significant effect on phosphorylation by
CaMKKα or CaMKKβ (Figure 6D).
AMPK is activated in a STO-609-sensitive manner
by depolarization in brain slices
Finally, we wished to test whether AMPK might be activated
by elevated intracellular Ca2+ in a more physiological setting.
Since CaMKKα and CaMKKβ are most highly expressed in
neural tissue, we examined the effects of neuronal depolariza-
tion in rat brain slices. Figure 7A shows that depolarization in-
duced by increasing concentrations of K+, which is known to
cause an increase in intracellular Ca2+ by opening of voltage-
gated Ca2+ channels, caused a 3-fold activation of AMPK that
was blocked by STO-609. By contrast, the antidiabetic drug
phenformin also activated AMPK in rat brain slices, but this
was not blocked by STO-609 (Figure 7B). Phenformin at 1 and
5 mM caused increasing elevation of the cellular ADP:ATP ratio
and an even larger elevation of the AMP:ATP ratio (Figure 7C).
However, K+-induced depolarization did not cause any change
in the ADP:ATP or AMP:ATP ratio, consistent with the idea that
this treatment activated AMPK via a Ca2+-dependent, and
AMP-independent, mechanism.
Discussion
In 1995, we demonstrated the phosphorylation and activation
of AMPK in cell-free assays by a preparation of CaMKK from
pig brain (Hawley et al., 1995). These findings were made prior
to the discovery of isoforms of this kinase, and the relative con-
centrations of CaMKKα and CaMKKβ in this preparation were13
A R T I C L EFigure 6. Activation of AMPK by CaMKKα and CaMKKβ in cell-free assays
(A) Various concentrations of a purified recombinant GST fusion of human
CaMKKβ were incubated with GST-α1 in 200 M ATP, 5 mM MgCl2, 50 mM Na-
HEPES (pH 7.0), 1 mM DTT, 0.02% (w/v) Brij-35, in the presence and absence
of 1 mM Ca2+ and 1 M calmodulin. After incubation for 10 min, AMPK activity
was determined. The results are expressed as nmol phosphate incorporated into
the substrate per minute per mg of GSTα1.
(B) Rat brain CaMKK was purified (Edelman et al., 1996), and the α and β iso-
forms were prepared by selective immunoprecipitation of the other isoform using14CaMKK and CaMKI were Ca /calmodulin dependent made it
commercial isoform-specific antibodies (Santa Cruz Biotechnology). Each super-
natant was analyzed by Western blotting using isoform-specific antipeptide anti-
bodies (Anderson et al., 1998).
(C) Activation of GST-α1 by CaMKKα and CaMKKβ. The isoforms prepared as in
(B) were diluted such that they gave a linear dependence on time and kinase
concentration, and activation of GST-α1 determined in the presence and absence
of Ca2+ and calmodulin as in (A) (mean ± SEM, n = 2).
(D) Effect of 100 M AMP on activation of AMPK by LKB1, CaMKKα, and
CaMKKβ (mean ± SEM, n = 3).Figure 7. Effect of various agents on activation of AMPK and cellular nucleotide
ratios in rat brain slices
Effects of (A) K+ depolarization and (B) phenformin, in the presence and absence
of 25 M STO-609, on the activity of AMPK in rat brain slices. In both cases,
data are presented as mean ± SEM, n = 3. (C) Effect of phenformin and K+
depolarization on ADP:ATP and AMP:ATP ratios in rat brain slices. Data are pre-
sented as mean ± SEM, n = 3.uncharacterized. At that time, this potential pathway for AMPK
activation seemed unlikely to be physiologically significant, for
several reasons. Firstly, the preparation of CaMKK activated
calmodulin-dependent protein kinase I (CaMKI) much more
rapidly than AMPK (Hawley et al., 1995), and the fact that both
2+CELL METABOLISM : JULY 2005
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ondly, we had partially purified from rat liver another protein
kinase that activated AMPK, termed AMPKK, that was clearly
distinct from CaMKK by several criteria, including lack of acti-
vation by Ca2+/calmodulin and a higher molecular mass by size
exclusion chromatography (Hawley et al., 1996). We subse-
quently identified AMPKK as a complex of LKB1, STRADα, and
MO25α but also obtained evidence that it could not account
for all of the upstream kinase activity acting on AMPK in intact
cells (Hawley et al., 2003). In particular, there appeared to be a
low but significant basal activity and phosphorylation of AMPK
in two cell lines that do not express LKB1, i.e., immortalized
fibroblasts (MEFs) derived from LKB1−/− mouse embryos, and
HeLa cells, where LKB1 is not expressed due to abnormal
methylation of promoter DNA (Tiainen et al., 1999). The results
in Figure 1 prove that the basal activity and the signal obtained
with the phosphospecific antibody against Thr-172 in extracts
of the LKB1−/− MEFs were indeed due to phosphorylation and
not due to possession of some residual activity by dephos-
phorylated AMPK or to lack of specificity of the antibody for
the phosphorylated form of AMPK.
We therefore reinvestigated whether CaMKKs might be
physiological activators of AMPK. Figures 2 and 3 show that
the Ca2+ ionophore A23187 caused a large activation of AMPK,
accompanied by phosphorylation at Thr-172, in HeLa cells that
expressed a kinase-inactive mutant of LKB1. It might be ar-
gued that Ca2+ ionophores would cause activation of ATP-
driven Ca2+ pumps consequent on Ca2+ entry into the cells and
that this could cause ATP depletion leading to activation of
AMPK as a secondary consequence. However, significant
changes in the cellular ATP:ADP ratio only occurred at concen-
trations of A23187 above 10 M, while the activation of AMPK
was already maximal at this concentration (Figure 2A).
The activation of AMPK by A23187 was antagonized by the
CaMKK inhibitor STO-609. Although STO-609 is not com-
pletely specific for the CaMKKs in cell-free assays, it causes
only slight inhibition of the other upstream kinase identified for
AMPK, i.e., the LKB1:STRAD:MO25 complex, at a concentra-
tion that gives complete inhibition of CaMKKs (Figure 4). STO-
609 does not inhibit LKB1 significantly in intact cells, because
the compound had no effect on the activation of AMPK by
phenformin in HeLa cells, even though the effect of phenformin
was completely dependent on expression of LKB1 (Figure 3).
However, we now report for the first time that STO-609 does
inhibit several other protein kinases significantly in cell-free as-
says (Figure 4). To remove any doubts as to whether the effects
of STO-609 were caused by inhibition of CaMKKs, we adopted
an siRNA approach. This revealed that we could significantly
reduce both the basal and the A23187-stimulated AMPK activi-
ties in LKB1-deficient HeLa cells using siRNAs targeted against
CaMKKβ but not CaMKKα (Figure 5). Both CaMKK isoforms
were expressed in the cells, and their expression could be
knocked down by treatment with the appropriate siRNA. Al-
though none of the CaMKKβ siRNAs completely abolished
AMPK activation, they did not completely downregulate CaMKKβ
protein expression, either. The siRNA (β3) that was most effec-
tive at downregulating CaMKKβ expression was also the most
effective at reducing basal and A23187-stimulated AMPK ac-
tivity. These results suggest that CaMKKβ is the dominant iso-
form mediating Ca2+-dependent activation of AMPK in HeLaCELL METABOLISM : JULY 2005cells, although they do not exclude the possibility that CaMKKα
could activate AMPK in other cell types.
Using RT-PCR, Ishikawa et al. (2003) could not detect the
β-1 (65 kDa) or β-2 (60 kDa) isoforms of CaMKK in HeLa cells
but instead detected two other splice variants, β-3 and β-3x,
that would encode shorter versions (60 and 55 kDa) of the pro-
tein. The β-3x protein, if expressed, would lack part of the cata-
lytic domain and may be inactive. Using an antibody against
an N-terminal epitope (Anderson et al., 1998) that should re-
cognize all splice variants, we detected a single major species
by Western blotting in HeLa cells whose mobility on SDS-
PAGE was consistent with a mass of 65 kDa (Figure 5B) and
which comigrated with the major form expressed in mouse
brain (data not shown). On other blots (data not shown), we
also detected a faint band migrating at around 60 kDa. Ishi-
kawa et al. (2003) did not perform any Western blotting studies
in their line of HeLa cells, so it is not easy to make a direct
comparison with their results.
The original studies on activation of AMPK by CaMKKs in
cell-free assays (Hawley et al., 1995) were performed with a
preparation from pig brain in which the isoform composition
was undefined. We therefore examined whether CaMKKα and
CaMKKβ could reactivate AMPK in a Ca2+- and calmodulin-
dependent manner. The results in Figure 6, using either recom-
binant human CaMKKβ expressed as a GST fusion in bacteria,
or CaMKKα and CaMKKβ derived by selective immunoprecipi-
tation from a rat brain preparation containing both isoforms,
show that both CaMKKα and CaMKKβ could activate AMPK
in a manner that is stimulated by Ca2+ and calmodulin. How-
ever, when the concentrations of CaMKKα and CaMKKβ were
adjusted so that they gave equal activation of CaMKI, CaMKKβ
was 7-fold more active against AMPK than CaMKKα. This rein-
forces the results obtained with siRNAs in intact cells, suggest-
ing that CaMKKβ is the dominant isoform with respect to regu-
lation of AMPK (Figure 5).
Activation of the AMPK heterotrimer by CaMKKα and
CaMKKβ was not significantly stimulated by AMP, although in
the same experiment its activation by the LKB1 complex was
stimulated 2.4-fold (Figure 6D). This differs from our earlier
findings in which phosphorylation of AMPK by a preparation of
CaMKK from pig brain was stimulated 2-fold by AMP (Hawley
et al., 1995). However, the content of the CaMKK preparation
used in that study was not completely defined, and we cannot
rule out the possibility that it was contaminated with LKB1 or
some other kinase that can phosphorylate Thr-172 in cell-free
assays. Our present results using more well-defined prepara-
tions of the upstream kinases show that the substrate-medi-
ated effect of AMP on activation is observed with LKB1 but not
the CaMKKs. This suggests that the conformational change
produced by binding of AMP to AMPK does not simply remove
a steric hindrance to Thr-172 phosphorylation but that a more
complicated mechanism is involved, such as the unmasking of
a docking site for LKB1.
Is the phosphorylation and activation of AMPK by CaMKKα
or CaMKKβ a physiologically significant event? At both the
mRNA and protein levels, expression of CaMKKα and CaMKKβ
is much higher in the brain than in other organs. Low levels of
expression are also observed for CaMKKβ in testis, thymus,
and spleen, although CaMKKα appears to be restricted to neu-
ral tissues (Anderson et al., 1998). We therefore hypothesized
that neural tissue was one site where activation of AMPK by15
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AMPK was activated in rat brain slices by K+-induced depolar-
ization, a treatment known to cause opening of voltage-gated
Ca2+ channels. This was completely blocked by the CaMKK
inhibitor STO-609 and was not associated with a change in
cellular ADP:ATP or AMP:ATP ratios. By contrast, phenformin
also activated AMPK in rat brain slices under the same condi-
tions, but this was not blocked by STO-609 and was associ-
ated with large increases in the ADP:ATP or AMP:ATP ratios
(Figure 7). Phenformin and the related biguanide metformin (the
latter a widely used antidiabetic drug) have both been reported
to inhibit complex I of the respiratory chain (El-Mir et al., 2000;
Owen et al., 2000). Although we (Hawley et al., 2002) and others
(Fryer et al., 2002) were unable to detect changes in cellular
nucleotides when cells were incubated with metformin, we
have consistently seen increases in ADP:ATP or AMP:ATP ratio
in several different cell types on incubation with the more po-
tent biguanide, phenformin (S.A.H., unpublished data). Our
present results suggest that the effect of K+-induced depolar-
ization in brain slices is mediated by one or more of the CaMKK
isoforms, while the effect of phenformin is mediated by a dif-
ferent upstream kinase, most likely LKB1.
While this work was in progress, Leclerc and Rutter (2004)
reported that K+-induced depolarization caused Thr-172 phos-
phorylation and activation of AMPK in MIN-6 cells and that this
was blocked by the calmodulin antagonist KN-62. The activa-
tion of AMPK occurred despite the finding that K+-induced de-
polarization increased the concentration of cytosolic ATP,
which might be expected to inhibit phosphorylation of AMPK
by LKB1. MIN-6 cells are a cell line derived from pancreatic β
cells, which are in turn thought to be of neural origin. It is there-
fore possible that the effects observed by Leclerc and Rutter
(2004) are also mediated by CaMKKβ.
Recently, Altarejos et al. (2005) have reported evidence in
support of an upstream kinase for AMPK, distinct from LKB1,
in extracts of ischemic heart. Ischemia appeared to cause a
stable increase in the activity of this unidentified protein kinase.
Since activation of CaMKKβ by Ca2+/calmodulin is through
noncovalent binding and would not be expected to be stable
during extraction and purification, and since CaMKKβ is not
expressed significantly in the heart (Anderson et al., 1998), it is
not clear whether the activity described by Altarejos et al.
(2005) is CaMKKβ.
One physiological event in which a Ca2+-dependent activa-
tion of AMPK by CaMKKs might be expected to be relevant is
contraction in skeletal muscle, which is known to be associ-
ated with increases in cytoplasmic Ca2+ and where AMPK is
activated (Winder and Hardie, 1996). However, we have re-
cently shown that AMPK activation by contraction is abolished
in mice in which LKB1 expression in muscle has been knocked
out by gene targeting (Sakamoto et al., 2005). AMPK activation
during contraction was associated with an increase in the cel-
lular AMP:ATP ratio and was completely dependent on LKB1.
Consistent with these findings, we have been unable to detect
expression of CaMKKα or CaMKKβ in mouse skeletal muscle
by Western blotting (data not shown).
Overall, our results now suggest that two signaling pathways
feed into the AMPK system, one mediated by LKB1 and trig-
gered by changes in the cellular AMP:ATP ratio and one medi-
ated by CaMKKβ and triggered by a rise in intracellular Ca2+.
In HeLa or MEF cells, agents that either increase intracellular16AMP (e.g., phenformin) or the AMP analog ZMP (AICA riboside)
do not activate AMPK unless the cells are expressing active
LKB1 (Hawley et al., 2003), even though CaMKKβ is expressed
in the cells. Thus, a rise in AMP alone does not appear to be
sufficient to stimulate phosphorylation of AMPK by CaMKKβ,
consistent with our findings that AMP does not significantly
stimulate activation of the AMPK complex by CaMKKβ in cell-
free assays. However, most conditions that cause a rise in intra-
cellular Ca2+ would be accompanied by an increased demand
for ATP, due in part to activation of Ca2+ pumps on the plasma
membrane and/or on intracellular membranes. Activation of AMPK
under these circumstances would increase glucose uptake by
GLUT1 (Barnes et al., 2002), and, along with effects of Ca2+ on
mitochondrial dehydrogenases involved in oxidative phosphor-
ylation (Nichols and Denton, 1995), this would increase genera-
tion of ATP. We suspect that this Ca2+-mediated pathway of
AMPK activation is most likely to have an important role in neu-
ral tissue. Studies using tissue-specific knockouts of LKB1
and/or CaMKKβ in mice should now enable the relative contri-
bution of these two pathways in different tissues to be delin-
eated.
Finally, modest elevations of intracellular Ca2+ provoked by
K+ depolarization have been shown to promote the survival of
diverse types of neurons (Franklin and Johnson, 1994; Moulder
et al., 2003), an effect that may be mediated by CaMKKs
(Schumacher et al., 2004; Yano et al., 1998). Since AMPK may
also contribute to the survival of neurons under stress condi-
tions (Culmsee et al., 2001), an implication of the results pre-
sented here is that the preservation of ATP levels by signaling
from CaMKK to AMPK may represent one arm of such a neu-
ronal survival pathway. Pharmacological recruitment of this
pathway may provide a novel therapeutic strategy in acute or
chronic neurodegenerative conditions.
Experimental procedures
Materials and antibodies
STO-609 was from Tocris, Ellisville, Missouri, and A23187 from Sigma,
Poole, Dorset, UK. Calmodulin was from Calbiochem, Merck Biosciences
Ltd., Nottingham, UK. The catalytic subunit of protein phosphatase-2A
(PP2A) was purified from bovine heart using methods previously described
for rabbit skeletal muscle (Cohen et al., 1988). AMPK antibodies (anti-α1,
anti-α2, and phosphospecific antibodies against Thr-172 [anti-pT172]) have
been described previously (Sugden et al., 1999; Woods et al., 1996). Anti-
CaMKKα antibodies were from rabbit and were raised against rat se-
quences, either residues 1–73 (sc-11370, from Santa Cruz Biotechnology)
or residues 488–505 (Anderson et al., 1998). Anti-CaMKKβ antibodies were
raised against rat sequences and were either goat antibodies against a
C-terminal peptide (sc-9629, from Santa Cruz Biotechnology) or a rabbit
antibody against an N-terminal peptide (residues 28–49) (Anderson et al.,
1998).
Cell lines
MEF cells from LKB1+/+ and LKB1−/− embryos (Hawley et al., 2003), and
HeLa cells expressing active LKB1 and a kinase-inactive mutant of LKB1
(Sapkota et al., 2002), have been described previously.
cDNA cloning and expression of human CaMKKβ
DNA encoding CaMKKβ was cloned from human brain cDNA (BD Biosci-
ences Clontech). The DNA was amplified using the DNA Hot Start DNA
Polymerase PCR Kit (Novagen). The primers were designed to amplify
CAMKKβ DNA with 5#-BamHI and 3#-KpnI ends. The 1.6 kb PCR product
was cloned into pGEX-6P-2 (Amersham Biosciences) using those restriction
sites. For expression, 200 ml of 2× YTA medium (3.2 g tryptone, 2 g yeast
extract, and 1 g NaCl [pH 7.0], containing 100 mg/ml ampicillin) was inocu-CELL METABOLISM : JULY 2005
Calmodulin-dependent kinase kinases and AMPKlated with an overnight culture (1 ml) of Escherichia coli BL21 (DE3) that
had been transformed with the pGEX-6P-2 CaMKKβ construct. Cultures
were grown at 37°C until the absorbance at 600 nm reached 1.0, after which
isopropylthiogalactoside (0.5 mM) was added to induce expression of the
CAMKKβ protein. Cells were recovered by centrifugation 4 hr later. Pellets
were resuspended in 10 ml phosphate-buffered saline (PBS) containing 1 mg/ml
lysozyme, 1 mM dithiothreitol (DTT), and Complete Protease Inhibitor Cock-
tail (Roche). Following incubation on ice for 30 min, Triton X-100 (1% v/v)
and DNase I (10 mg/ml) were added to the cell lysate. The lysate was vor-
texed and left on ice for 5 min before being clarified by centrifugation at
300,000 × g for 1 hr. The lysate was applied to a 5 ml GST HiTrap affinity
column (Amersham Biosciences) that had been preequilibrated with 30 ml
PBS. The column was washed with 30 ml PBS containing 1 M NaCl, 1 mg/ml
lysozyme, 1 mM DTT, and Complete Protease Inhibitor Cocktail (Roche)
followed by 30 ml of the same buffer lacking NaCl. The GST fusion was
eluted with 20 ml PBS (pH 7.4) containing 10 mM reduced glutathione.
Fractions containing protein were concentrated using centrifugal ultrafiltra-
tion (Biomax 10K, Millipore).
Purification of AMPK, LKB1, CaMKKα, and CaMKKβ from rat tissues
AMPK (from rat liver [Hawley et al., 1996]), LKB1 (from rat testes, purified
as in Hawley et al. [2003]) and CaMKK-α and -β (from rat brain [Edelman et
al., 1996]) were purified as described previously. The α and β isoforms of
CaMKK were subsequently resolved by immunoprecipitation with an excess
of anti-CaMKKβ or -CaMKKα antibody (Santa Cruz Biotechnology), yielding
a supernatant containing the other isoform.
Kinase assays and Western blotting
Kinase assays in solution and in immunoprecipitates for AMPK, and analysis
of Western blots using antipeptide antibodies using dual labeling of phos-
phospecific and phosphorylation-independent probes, have been described
previously (Hawley et al., 2003).
Effect of AMP on activation of AMPK by upstream kinases
AMPK was purified from rat liver to the gel filtration stage and was inacti-
vated by 95% by treatment with the catalytic subunit of PP2A, which was
subsequently inhibited by the addition of okadaic acid to a final concentra-
tion of 100 nM (Hawley et al., 1996). Dephosphorylated AMPK was incu-
bated with either LKB1, CaMKKα, or CaMKKβ (the latter in the presence of
1 mM Ca2+ and 1 M calmodulin) in 200 M ATP, 5 mM MgCl2, 50 mM Na-
HEPES (pH 7.0), 1 mM DTT, and 0.02% (w/v) Brij-35 in the presence or
absence of 100 M AMP and (for CaMKKα or CaMKKβ) in the presence of
1 mM Ca2+ and 1 M calmodulin. The concentrations of upstream kinases
were adjusted so that all were in the linear range (i.e., the degree of activa-
tion was proportional to the amount added) and so that all gave approxi-
mately the same degree of activation in the absence of AMP. After incuba-
tion for 10 min, AMPK activity was determined. The results are expressed
as units (nmol phosphate incorporated per minute) per mg of AMPK protein.
siRNA studies
Predesigned siRNAs directed against CaMKKα and CaMKKβ, Silencer
Negative Control 1, and GAPDH siRNA control were purchased from Am-
bion (Cambridgeshire, UK). The three siRNAs (ID 40538 [α1], 40721 [α2],
and 103383 [α3]) used to silence CaMKKα expression are targeted against
all three transcript variants, which encode two distinct isoforms. Similarly,
the siRNAs (ID 815 [β1], 816 [β2], and 110916 [β3]) used to silence CaMKKβ
expression are targeted against all seven transcript variants, which encode
six distinct isoforms. Individual siRNAs were used at a final concentration
of 50 nM. HeLa cells were seeded in 60 mm2 dishes at 0.8 × 106 cells per
dish 24 hr prior to transfection. siPORT Lipid (Ambion) was used according
to the manufacturer’s instructions for transfection of the siRNA into the
cells. After transfection, cells were incubated for 48 hr and then treated with
or without A23187.
Treatment of MEF immunoprecipitates with protein phosphatase
MEF cells from LKB1+/+ and LKB1−/− embryos were treated with or without
10 mM phenformin, then total AMPK was immunoprecipitated from the ly-
sate (800 g protein) as described previously (Hawley et al., 2003). AMPK
was incubated with the catalytic subunit of PP2A (10 mU/ml) for 10 min inCELL METABOLISM : JULY 2005the presence or absence of 100 nM okadaic acid and AMPK activity and
the phosphorylation state of Thr-172 determined as described above.
Assays to test specificity of STO-609
AMPK (assayed using SAMS peptide as substrate [Davies et al., 1989]),
LKB1 (assayed using LKBtide [Lizcano et al., 2004]), and CaMKKα and
CaMKKβ (assayed by their ability to activate the kinase domain of AMPK
[Hawley et al., 2003]) were assayed in the presence of various concentra-
tions of STO-609. Screening of other protein kinases using a single concen-
tration of STO-609 was as described previously (Bain et al., 2003).
Preparation and incubation of rat brain slices
Rat brain cerebrocortical slices, comprising sagittal sections of hippocam-
pus and overlying neocortex, were prepared from 22- to 30-day-old
Sprague-Dawley rats and incubated as described previously (Gadalla et al.,
2004). Slices were maintained in an incubation chamber at room temper-
ature for 30 min and then at 34°C for at least another 2.5 hr. After this
preincubation period, individual slices were placed in experimental cham-
bers (34°C) containing KCl (3, 10, 30 mM) or phenformin (1, 5 mM) for 5
min or 30 min, respectively. In studies using the CaMKK inhibitor, slices
were preincubated for 20 min in STO-609 (25 M), after which KCl or phen-
formin was added at the indicated final concentration. After incubation,
slices were snap frozen in liquid N2 and stored at −80°C for subsequent
homogenisation and biochemical analysis. Duplicate slices were used for
each treatment, and each treatment was repeated with slices from three
different rats.
Analysis of cellular nucleotide ratios
Nucleotide ratios were determined after perchloric acid extraction of rat
brain slices (Gadalla et al., 2004) using capillary electrophoresis (Sakamoto
et al., 2005).
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